In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
Transcript
How are restrictive eligibility criteria contributing to keeping minority patients out of clinical trials?
So, we found within our cohort that African Americans were more likely to have kidney dysfunction compared with the white population. So, this means that clinical trials that include eligibility criteria that exclude patients with renal dysfunction may be disproportionately excluding patients with kidney disease, such as the African American patient population.
From a more broad perspective, this means that eligibility criteria may be systematically excluding African Americans from clinical trials because they have higher rates of renal dysfunction compared to the white patient population.
Are these restrictive eligibility criteria necessary or is there an argument to be made that these criteria should be relaxed?
So, for specific clinical trials it may still be appropriate to include restrictive eligibility criteria. So, I’ll give you an example. For clinical trials including interventions that are metabolized through the liver or excreted through the kidneys, it may be appropriate to still exclude patients who have minor liver or renal dysfunction.
However, for other clinical trials, our outcomes suggest that it may be appropriate to relax those eligibility criteria, and include patients who have minor renal or liver dysfunction as their outcomes are not significantly different than those patients who don’t have such abnormalities prior to the initiation of therapy.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More